Citi launched its coverage of Cytokinetics (NASDAQ:CYTK) with a Buy recommendation, noting that the cardiac drug developer’s recent selloff is overdone given that its lead asset, aficamten ...

Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $86 price target. The shares seem attractive at current levels, given the “substantial opportunity” for aficamten ...

BofA notes that Cytokinetics (CYTK) shares are under pressure this morning after rival Bristol Myers (BMY) confirmed European regulators had eased Camzyos’ maintenance echo monitoring ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks that analysts are talking about. Like any other informed investor ...

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

Cytokinetics' aficamten shows strong potential in the $3B U.S. oHCM market, despite competition from Bristol Myers’ Camzyos. Stifel sets a $80 price target, highlighting catalysts expected over ...

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...